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Abstract: Systemic candidiasis is an opportunistic infection caused by Candida species in animals. The purpose of this study was to
evaluate the pathogenicity of different doses of Candida zeylanoides in BALB/c mice. Thirty mice were selected in this study. Different
doses of the yeast were intravenously inoculated to the animals. At first, clinical signs and survival time of infected mice were recorded.
Then both mycological and histological examinations were performed for detection of Candida in different tissues. The results showed
that the injection of 1 × 108 cells of C. zeylanoides caused high mortality (group 1). The mortalities occurred within 7–12 days (mean:
9.5 days) in group 2 (inoculated with 2 × 107 yeast) and 15–25 days (mean: 20 days) in group 3 (inoculated with 1 × 107 yeast cells) after
infection. The kidneys had the highest burden of yeasts (6 × 104 CFU/g). The results of histological examination showed masses of round
to oval budding yeast cells along with a few pseudohyphae in different tissues. These results provide evidence that the pathogenicity of
C. zeylanoides is directly related to the inoculum size of the infecting species, representing the highest yeast burden in the kidneys of
the infected BALB/c mice. In order to obtain the exact virulence factors in C. zeylanoides, this study should be continued in the future.
Key words: Candida zeylanoides, pathogenicity, virulence, mice

1. Introduction
The frequency of invasive fungal infections has increased
significantly over the past 2 decades (1,2). This increase
in infection is associated with excessive morbidity and
mortality (3) and is directly related to the increasing numbers
of patients who are at risk for the development of serious
fungal infections, including patients undergoing blood and
marrow transplantation, solid-organ transplantation, and
major surgery (especially gastrointestinal surgery); patients
with AIDS, neoplastic disease, and advanced age; patients
receiving immunosuppressive therapy; and premature
infants (4,5). Members of the genus Candida are natural
inhabitants of the skin, gastrointestinal, genital, and upper
respiratory tracts of humans and animals (6). Candida
species were reported to be the fourth most common
cause of bloodstream infections with high mortality rates
(7). They were isolated as causative agents in 10%–15%
of all nosocomial infections, 70%–80% of all nosocomial
fungal infections, and 8%–10% of nosocomial bloodstream
infections (8). C. albicans, C. glabrata, C. tropicalis, and C.
parapsilosis were the most frequently encountered causative
agents in systemic candidiasis (9,10).
* Correspondence: khosravi@ut.ac.ir
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C. zeylanoides is relatively rare in humans and animals,
but it is included in the Atlas of Clinical Fungi (11) and has
been reported on skin, nails, and blood as an opportunistic
yeast pathogen and also in a report of endocarditis in
an HIV-positive patient (12–15). Hazen (14) described
C. zeylanoides as a new and emerging pathogen and
observed that this yeast could be isolated from blood
cultures repeatedly, indicating a constant shedding into
the bloodstream. In previous studies, this fungus has been
reported from the skin of a bottlenose dolphin in Japan
and the genital tract of Iranian female camels (16,17). The
purpose of this study was to investigate the pathogenicity
of different doses of C. zeylanoides in BALB/c mice. Since
this study has proven this fungus can invade tissues in
this exact condition, it seems it will be categorized as an
emerging opportunistic fungus in the future.
2. Materials and methods
2.1. Organism and growth conditions
Candida zeylanoides CA534, originally isolated from the
genital tract of female camels, was cultured on Sabouraud
dextrose agar containing chloramphenicol (0.005%,
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and 40 µg/mL streptomycin). The plates were incubated at
35 °C for 14 days, and fungal colonies were counted and
expressed as colony forming units (CFUs) per gram of
tissue.
For histological examination, tissue samples were fixed
in 10% neutral buffered formalin, embedded in paraffin
wax, sectioned at 5–7 µm, and stained with hematoxylin
and eosin (HE). Selected sections were stained with
periodic acid-Schiff (PAS) as well.

Merck Co., Darmstadt, Germany) at 35 °C for 24 h. For
re-identification of the yeast CHROM agar, β-glucosidase
test, urease test, sugar fermentation, and assimilation
tests by RAPID yeast plus system (Remel Inc., USA) were
used as major taxonomic criteria. Yeast cells from at least
5 colonies 1 mm in diameter were suspended in 5 mL of
sterile 0.85% saline, and cell concentrations were adjusted
using a hemocytometer. The viable count was confirmed
by serially diluting the yeast suspension 10-fold and plating
each inoculum onto Sabouraud dextrose agar plates.
2.2. Experimental systemic candidiasis
Thirty female BALB/c mice, weighing 25 to 30 g, were
purchased from the Razi Institute of Iran. The animals
were kept under standard conditions in an animal house
at the Faculty of Veterinary Medicine, Tehran, Iran. They
were divided into 6 groups (5 mice [A, B, C, D, E] per each
group) and infected as follows: group 1 was inoculated
intravenously with 1 × 108 cells, group 2 was inoculated
intravenously with 2 × 107 cells, group 3 was inoculated
intravenously with 1 × 107 cells, group 4 was inoculated
intravenously with 5 × 106 cells, group 5 was inoculated
intravenously with 1 × 106 cells, and a control group in
which the mice were inoculated intravenously with sterile
normal saline. Clinical signs and survival time were
evaluated for 4 weeks after yeast inoculation.
2.3 Tissue culture and pathology
All the euthanized mice and those that died spontaneously
were subjected to detailed necropsy examinations under
aseptic conditions.
For tissue culture, representative tissue samples from
the brain, lungs, kidneys, liver, and spleen of the infected
animals were removed, placed in glass vials containing
10 mL of sterile saline, and subsequently homogenized.
One hundred milligrams of the homogenates was made in
sterile normal saline and cultured on Sabouraud dextrose
agar containing antibacterial antibiotics (20 IU penicillin

3. Results
Clinically early deaths occurred 2–4 days postinoculation
(PI) in group 1, and neurological signs such as circling,
ataxia, severe movements of the head, tilting of the head
and neck towards one side, and somnolence in groups 2,
3, and 4 were monitored. These signs were observed more
severely in group 3. The mortalities occurred within 7–12
days PI in group 2 and 15–25 days PI in group 3. Although
no animals died in groups 4 and 5, in group 4 animals had
mild clinical signs. The animals in groups 4, 5, and the
control group were euthanized 30 days PI (Table 1).
The results of tissue cultures are given in Table 2 as log
CFU/g. The highest burden of C. zeylanoides was found in
the kidneys, followed by the brain, lungs, liver, and spleen
in all treatment groups (Figure 1).
In the histological examinations, masses of round to
oval budding yeast cells (blastospores) measuring 3–5 µm in
diameter along with a few pseudohyphae in different tissues
were observed. Focal necrosis with glial cell aggregation,
perivascular cuffing, hemorrhage zones around vessels,
focal gliosis, and vascular edema accompanying the yeast
cells inside the macrophages were determined in the brain
(Figure 2). Mostly, multifocal necrosis, hemorrhage, and
mononuclear interstitial infiltrations were detected in the
kidneys (Figure 3). Infiltration of polymorphonuclear cells
(PMNs) and hyperemia were predominant in the lungs.
Numerous aggregations of yeast cells were observed in

Table 1. Clinical signs and mean CFU/g of different doses of C. zeylanoides in treatment groups.
Tissue culture (mean CFU/g)

Groups

Yeast dose

Clinical signs

Mean survival
time (days)

Brain

Kidneys

Liver

Spleen

Lungs

1

1 × 108

Early death

2

2 × 103

1 × 104

7 × 103

2 × 103

1.1 × 103

2

2 × 107

Slight neurological symptoms

9.5

3.5 × 103

1.4 × 104

2 × 103

1 × 103

1.4 × 104

3

1 × 107

20

1.4×104

1.6 × 104

2 × 103

3 × 102

1.4 × 104

4

5 × 106

Euthanized

0

6 × 104

3 × 102

3 × 102

0

5

1 × 10

Ataxia, circling, somnolence,
anorexia
Neurological signs at first but
recovered after 30 days
No clinical signs

Euthanized

0

0

0

0

0

Control

–

No clinical signs

Euthanized

0

0

0

0

0

6
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Table 2. Log CFU/g in different tissues of treatment groups*.

(Mice inoculated with 108
yeast cells)
(Mice inoculated with
2 × 107 yeast cells)
(Mice inoculated with
1 × 107 yeast cells)
(Mice inoculated with
5 × 106 yeast cells)
(Mice inoculated with
1 × 106 yeast cells)

Group 5

Group 4

Group 3

Group 2

Group 1

Groups

Mice

Brain

Kidneys

Liver

Spleen

Lungs

A

3.23

3.96

3.74

3.00

2.95

B

3.34

4.13

3.85

3.40

3.15

C

3.43

3.99

3.88

3.18

3.00

D

3.26

3.99

3.90

3.40

2.90

E

3.30

3.91

3.85

3.48

3.11

mean

3.32

4.00

3.85

3.32

3.03

Mice

Brain

Kidneys

Liver

Spleen

Lungs

A

3.59

4.13

3.45

3.30

4.17

B

3.48

4.23

3.23

3.04

4.10

C

3.58

4.13

3.34

3.26

4.15

D

3.59

4.07

3.26

3.46

4.12

E

3.45

4.16

3.11

3.38

4.20

mean

3.54

4.15

3.29

3.31

4.15

Mice

Brain

Kidneys

Liver

Spleen

Lungs

A

4.11

4.32

3.48

2.32

4.19

B

4.21

4.06

3.18

2.54

4.12

C

4.23

4.18

3.26

2.43

4.16

D

4.03

4.27

3.32

2.52

4.18

E

4.17

4.14

3.28

2.58

4.08

mean

4.16

4.20

3.31

2.49

4.15

Mice

Brain

Kidneys

Liver

Spleen

Lungs

A

–

4.80

2.26

2.28

–

B

–

4.76

2.43

2.45

–

C

–

4.86

2.56

2.58

–

D

–

4.68

2.60

2.61

–

E

–

4.76

2.49

2.32

–

mean

–

4.78

2.48

2.47

–

Mice

Brain

Kidneys

Liver

Spleen

Lungs

A

–

–

–

–

–

B

–

–

–

–

–

C

–

–

–

–

–

D

–

–

–

–

–

E

–

–

–

–

–

mean

–

–

–

–

–

*No clinical signs were observed in control group.
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Figure 1. The mean CFU/g of yeast cells in different tissues of
studied groups.

the brain (Figure 4), but single or few yeast cells with buds
were determined in the other studied tissues.

Figure 2. Mouse, group 3. Focal gliosis and yeast cells into the
macrophages in the brain section of infected mice. HE, 1000×.

4. Discussion
Candida infections are a growing problem among
immunocompromised subjects (1). Although most
episodes of candidiasis are still caused by C. albicans,
opportunistic infections due to other Candida species
have been reported with increasing frequency (18). There
is little information regarding C. zeylanoides pathogenicity
(5,9). The involvement of this yeast in fungemia,
arthritis, endocarditis, and skin infections in humans
was documented (13,14). In a study by Shokri et al. (16),
C. zeylanoides was isolated as the predominant (20.3%)
yeast flora in the genital tract of Iranian female camels.
In the present study, a systemic candidiasis was induced
in BALB/c mice following intravenous inoculation of C.
zeylanoides and observations were recorded until death.
Clinical signs observed in the infected mice were initially
characterized by circling, ataxia, and neurological signs
along with restlessness in the later stages. These findings
can be attributed to severe stress due to systemic fungal
infections, which are compatible with previous reports
with experimental candidiasis in other animal models
(19).
The results of this study showed that an injection of
1 × 108 yeast cells leads to early death in mice, with the
average survival time of 2 days. In a previous study, by
Riazipour et al. (20), the mean survival time in BALB/c
mice infected with C. albicans (1 × 106 cells intravenously)
was determined as approximately 12.4 days. In our study
animals in group 5 that were inoculated with the same
dose as C. albicans did not reveal any clinical signs during
the 30 days. Interestingly, for the mice in group 2, which
were injected with 2 × 107 yeast cells, the survival time was
up to 9.5 days. It seems that the survival time in the abovementioned dose is close to injection with 1 × 106 cells of
C. albicans. In comparison to C. albicans, C. zeylanoides

is less virulent and indicates a higher survival time in
infected animals. In a previous study, the esterase activities
of C. albicans and C. zeylanoides isolates were evaluated.
It was revealed that enzymatic activity of C. zeylanoides
was weak, whereas C. albicans showed strong enzymatic
activity (21). It seems that esterase and other enzymes have
important roles in Candida invasion.
In this study, the presence of fungal elements in
different tissues, especially in the kidneys and brain,
and perivascular invasion were the most predominant
microscopic characteristics of systemic candidiasis.
The histological findings were initially characterized by
congestion and hemorrhages in different tissues along
with focal areas of necrosis. These were followed by the
development of multiple microabscesses in the kidneys,
brain, lungs, liver, and spleen, in order of severity. Mean
infection rate was significantly higher in the kidneys (6
× 104 CFU/g) than it was in the other organs. Brown et
al. (22) reported that Candida organisms multiplied to
a greater extent in the kidneys than in the liver, spleen,
and lungs of rats and mice. As mentioned, discrepancy in
Candida distribution is dependent on the animal species
challenged, the growth conditions used for the challenge
inoculum, differences between fungal strains, and the
route of Candida species inoculation.
Many studies have reported kidney fungal burden
as the primary endpoint when analyzing the virulence
and/or the susceptibility of Candida species in mice
with systemic candidiasis (23,24). Importantly, there
are significant differences among the endothelial cells
that line the vasculature of the different organs, as well
as the immunologic milieu of these organs (25). These
differences provide a compelling rationale to investigate
the capacity of Candida species to traffic to and persist in

411

KHOSRAVI et al. / Turk J Vet Anim Sci

Figure 3. Hemorrhage zones in the kidneys with numerous yeast
cells. HE, 400×.

organs other than the kidney. The brain is a particularly
important target organ in subjects with hematogenously
disseminated candidiasis (26). To invade the brain
parenchyma, blood-borne Candida cells must adhere to
and traverse the endothelial cell lining of the blood vessels
within the central nervous system. Brain endothelial cells
are significantly different from those lining systemic blood
vessels. For example, they have tight junctions that are not
present in the endothelial cells in other vascular beds (27).
In conclusion, an increase in inoculum size was
associated with an increase in the mortality rate of the
infected mice. The highest counts of C. zeylanoides

Figure 4. Mouse, group 3. Presence of different shapes of yeasts
in the brain tissue of infected mice. PAS, 1000×.

were recovered from the kidneys, followed by the brain,
lungs, liver, and spleen. We suggest that use of survivalstandardized inocula provides a novel approach for future
investigations to differentiate early- and late-stage host and
pathogen factors involved in the infectious disease process
with this fungus. Since the various components of the cell
wall and cytoplasm of Candida species are important in
the pathogenicity, this study should be continued to obtain
the exact virulence factors in C. zeylanoides.
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